Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Completed · Phase 2
Conditions studied: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
In brief
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation from related donors to prevent graft-versus-host disease in treating patients with hematologic cancer.
Key facts
- Study ID
- NCT00003396
- Run by
- University of Maryland, Baltimore
- People needed
- 42
- Starts
- 1998-09-01
- Expected to finish
- 2002-12-01
- Last updated by the study team
- 2019-10-17
Who can join
Age: any, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Marlene & Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.